Zolmitriptan
Generic Details
Generic Name
Zolmitriptan
Other Names
- Zomig
Drug Class
- Antimigraine Agent
Chemical Formula
C16H21N3O2S
Molecular Weight
303.43 g/mol
Mechanism of Action
- Selective agonist for serotonin (5-HT1B/1D) receptors
Indications
- Acute treatment of migraine attacks with or without aura in adults
Common Dosage Forms
- Tablet
- Orally disintegrating tablet
Typical Dosage
- 2.5-5 mg once during a migraine attack; may repeat after 2 hours if needed, not to exceed 10 mg in 24 hours
Pediatric Dosage
- Safety and efficacy not established in children under 18 years
Geriatric Dosage
- Dose adjustment may be necessary based on renal function
Side Effects
- Dizziness
- Drowsiness
- Paresthesia
- Chest discomfort
- Dry mouth
- Nausea
Contraindications
- Ischemic heart disease
- Uncontrolled hypertension
- History of stroke or transient ischemic attack
- Peripheral vascular disease
- Severe hepatic impairment
Pregnancy Category
- C - Risk cannot be ruled out
Lactation Safety
- L2 - Safer: Drug has moderate levels of safety in lactation
Drug Interactions
- SSRIs
- MAOIs
- Ergotamine derivatives
- Other 5-HT1 agonists
Overdose Symptoms
- Dizziness
- Nausea
- Somnolence
- Vomiting
Antidote for Overdose
- General supportive measures
Storage Conditions
- Store at controlled room temperature (20-25°C)
Pharmacokinetics
- Absorption: Well absorbed after oral administration
- Distribution: Crosses the blood-brain barrier
- Metabolism: Extensively metabolized primarily by CYP1A2
- Excretion: Eliminated in urine (40%) and feces (60%)
Precautions
- Caution in patients with a history of epilepsy or seizures
- Monitor for signs of serotonin syndrome
Warnings
- Risk of coronary vasospasm
- May cause increases in blood pressure
Others
- Avoid use in patients with hemiplegic or basilar migraine